This page is an educational summary and does not constitute clinical guidance or a recommendation for use. Prescribing, dosing and treatment decisions should be made on the basis of individual patient assessment, current clinical guidelines and the treating healthcare professional's judgement.
What is THCV?
THCV (C₁₉H₂₆O₂) is a naturally occurring cannabinoid in Cannabis sativa. THCV is a propyl analogue of THC with a shorter side chain. Present at low concentrations in most cannabis but higher in certain African and Asian landrace varieties.
Pharmacology
Pharmacology is dose-dependent: CB1 antagonist at low doses (suppresses appetite, opposite of THC) and CB1 partial agonist at high doses. CB2 agonist. This dual profile makes THCV pharmacologically distinct and potentially useful in metabolic conditions.
Current Evidence
A Phase 2 trial in type 2 diabetes (Jadoon, Diabetes Care 2016) found THCV improved fasting glucose and adiponectin. No Phase 3 RCTs completed. Growing pharmaceutical industry interest in THCV for metabolic indications.
GMP Relevance
THCV at low concentrations in cannabis starting material should be included in cannabinoid profile specifications where present. Its distinct pharmacology from THC means it should not be assumed pharmacologically inert.
Regulatory Status
THCV is not independently scheduled as a controlled substance in most European jurisdictions as a component of cannabis starting material. Pharmaceutical preparations require EU GMP manufacturing standards. Specifications should include identity, purity and assay by validated HPLC.
See the Cannabis Glossary for definitions of related cultivation, extraction and quality terms.
References
- Jadoon KA et al. Efficacy of CBD and THCV on Glycemic Parameters in Type 2 Diabetes. Diabetes Care. 2016.
- McPartland JM et al. Affinity Studies of THCV at Cannabinoid Receptors. Br J Pharmacol. 2007.